Roxadustat Attenuates Adverse Remodeling Following Myocardial Infarction in Mice.

Marc-Michael ZarubaSimon StagglSanthosh Kumar GhadgeThomas MaurerJasmina Gavranovic-NovakovicVivek JeyakumarPatric SchönherrAndreas WimmerGerhard PölzlAxel BauerMoritz Messner

Published in: Cells (2024)

Our findings suggest that roxadustat is a promising clinically approved treatment option to preserve myocardial function by attenuating adverse remodeling.

Keyphrases

left ventricular
heart failure
high fat diet induced
metabolic syndrome
combination therapy
atrial fibrillation
smoking cessation